On May 1, the US Food and Drug Administration (FDA) announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the ...
On April 30, 2026, the U.S. Food and Drug Administration (FDA) announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List (“503B Bulks ...
The FDA has proposed excluding weight-loss drugs, such as Ozempic/Wegovy and Zepbound from a key compounding list, ...
In an effort to provide high-quality, cost-effective care, ASCs rely on outsourced human drug compounding to accommodate specific patient orders. Most centers don’t possess the appropriate staffing or ...
MedPage Today on MSN
FDA Intensifies Crackdown on GLP-1 Compounding
Agency proposal would exclude semaglutide, tirzepatide, and liraglutide from 503B bulks li ...
The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- ...
The FDA’s requirements for compounding sterile drugs have become more stringent in recent years, especially since 2016, following the addition of section 503B to the 2013 Drug Quality and Security Act ...
Ottawa, Oct. 08, 2025 (GLOBE NEWSWIRE) -- 503A U.S. Compounding Pharmacies Market Growth The global 503A U.S. compounding pharmacies market size was valued at USD 4.47billion in 2024 and is predicted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results